Physician profile
Ann Kuri
NPI 1215270277
$1,574.64
in general payments reported to CMS, 2019-2025
26 companies · $96.95 in 2025
The $96.95 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $15.53 · 2022: $121 · 2023: $373 · 2024: $715 · 2025: $96.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $628.84 | 2023-2024 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $156.36 | 2019-2024 | Jornay Pm |
| Sanofi Pasteur INC. | $110.22 | 2019-2024 | |
| Corium, LLC | $71.97 | 2023-2024 | Azstarys |
| Acadia Pharmaceuticals INC | $64.96 | 2023-2024 | Daybue |
| Tris Pharma INC | $55.26 | 2022-2023 | Dyanavel Xr |
| Pfizer INC. | $53.43 | 2022-2025 | |
| Shire North American Group INC | $39.00 | 2019 | |
| Neos Therapeutics, LP | $38.46 | 2019 | |
| Cranial Technologies, INC | $37.91 | 2022-2023 | Doc Band |
| Merck Sharp & Dohme LLC | $36.33 | 2024 | Gardasil 9, Vaxneuvance, Gardasil |
| Mylan Pharmaceuticals INC. | $26.27 | 2019 | |
| Aimmune Therapeutics, INC. | $23.82 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.49 | 2025 | Eohilia |
| Astrazeneca Pharmaceuticals LP | $22.22 | 2024 | Flumist Quadrivalent |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $20.78 | 2025 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $19.60 | 2024 | Ycanth |
| Glaxosmithkline, LLC. | $18.46 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $17.71 | 2025 | Kristalose |
| Novartis Pharmaceuticals Corporation | $17.23 | 2019 | |
| Sobi, INC | $16.98 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.87 | 2024 | Relexxii |
| Kaleo, INC. | $15.83 | 2022 | |
| Photonicare INC | $14.57 | 2024 | Otosight Middle Ear Scope |
| Alexion Pharmaceuticals, INC. | $14.15 | 2024 | |
| Abbott Laboratories | $13.92 | 2025 | Id Now Strep A 2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Kuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.